for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ZEAL.OQ

Latest Trade

26.95USD

Change

-0.55(-2.00%)

Volume

3,731

Today's Range

26.73

 - 

27.17

52 Week Range

11.30

 - 

28.85

As of on the NASDAQ Stock Exchange Global Select Market ∙ Minimum 15 minute delay

Latest Developments

Zealand Pharma Achieves Primary And All Key Secondary Endpoints In Pediatric Phase 3 Trial With Dasiglucagon

Sept 24 (Reuters) - Zealand Pharma A/S <ZELA.CO>::REG-ZEALAND PHARMA ACHIEVES PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN PEDIATRIC PHASE 3 TRIAL WITH DASIGLUCAGON FOR SEVERE HYPOGLYCEMIA.STUDY RESULTS SUPPORT USE OF SAME DOSE OF DASIGLUCAGON IN ADULTS AND CHILDREN.ON-TRACK FOR SUBMISSION OF NEW DRUG APPLICATION TO U.S. FDA IN EARLY 2020.OVERALL, NO SAFETY CONCERNS WERE RAISED FOR DASIGLUCAGON WITHIN TRIAL.PRIMARY RESULT DEMONSTRATED THAT MEDIAN TIME TO BLOOD GLUCOSE RECOVERY WAS 10 MINUTES FOR DASIGLUCAGON, WHICH WAS SUPERIOR TO PLACEBO (MEDIAN: 30 MIN; P<0.001).MEDIAN TIME TO RECOVERY FOR GLUCAGEN® WAS 10 MINUTES.OVERALL, NO SAFETY CONCERNS WERE RAISED FOR DASIGLUCAGON WITHIN TRIAL.

Zealand Pharma Says Van Herk Investments Holds Nominally DKK 6.7 Mln Shares In Co

Sept 5 (Reuters) - Zealand Pharma A/S <ZELA.CO>::REG-ZEALAND PHARMA MAJOR SHAREHOLDER ANNOUNCEMENT: VAN HERK INVESTMENTS.AS FROM 5 SEPTEMBER 2019, VAN HERK INVESTMENTS B.V. HOLDS NOMINALLY DKK 6.7 MILLION SHARES IN ZEALAND PHARMA A/S.VAN HERK INVESTMENTS B.V SHARES IN CO CORRESPONDS TO 18.75% OF TOTAL SHARE CAPITAL AND TOTAL VOTING RIGHTS IN CO.

Boehringer Ingelheim And Zealand Pharma Advance GLP-1/Glucagon Agonist BI 456906 To Phase 2 Clinical Testing

Sept 3 (Reuters) - Zealand Pharma A/S <ZELA.CO>::REG-BOEHRINGER INGELHEIM AND ZEALAND PHARMA ADVANCE DUAL-ACTING GLP-1/GLUCAGON AGONIST BI 456906 TO PHASE 2 CLINICAL TESTING IN OBESITY/DIABETES.PHASE 2 TRIAL FOR BI 456906 IS EXPECTED TO BE INITIATED IN LATE 2019 AND WILL TRIGGER A EUR 20 MILLION MILESTONE PAYMENT TO ZEALAND PHARMA OUT OF TOTAL OUTSTANDING POTENTIAL MILESTONE PAYMENTS OF EUR 365 MILLION AND HIGH SINGLE TO LOW DOUBLE DIGIT ROYALTIES ON FUTURE SALES.

Boehringer Ingelheim And Zealand Pharma Advance GLP-1/Glucagon Agonist To Phase 2 Clinical Testing

Sept 3 (Reuters) - BOEHRINGER INGELHEIM::BOEHRINGER INGELHEIM AND ZEALAND PHARMA ADVANCE DUAL-ACTING GLP-1/GLUCAGON AGONIST BI 456906 TO PHASE 2 CLINICAL TESTING IN OBESITY/DIABETES.DUAL ACTING GLP-1/GLUCAGON PEPTIDE BI 456906 IS A PART OF BOEHRINGER INGELHEIM’S PIPELINE PORTFOLIO IN OBESITY AND DIABETES.DUAL PHASE 2 TRIAL FOR BI 456906 IS EXPECTED TO BE INITIATED IN LATE 2019 AND WILL TRIGGER A EUR 20 MILLION MILESTONE PAYMENT TO ZEALAND PHARMA OUT OF TOTAL OUTSTANDING POTENTIAL MILESTONE PAYMENTS OF EUR 365 MILLION AND HIGH SINGLE TO LOW DOUBLE DIGIT ROYALTIES ON FUTURE SALES.

Zealand Pharma Appoints Matthew Dallas As New CFO

Aug 28 (Reuters) - Zealand Pharma A/S <ZELA.CO>::REG-ZEALAND PHARMA APPOINTS MATTHEW DALLAS AS NEW CHIEF FINANCIAL OFFICER.APPOINTMENT OF MATTHEW DALLAS AS VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, EFFECTIVE OCTOBER 7, 2019.

Zealand Pharma H1 Operating Loss Widens To DKK 272.1 Million

Aug 15 (Reuters) - Zealand Pharma A/S <ZELA.CO>::REG-ZEALAND PHARMA DELIVERS STRONG CLINICAL RESULTS DURING THE FIRST HALF OF 2019 AND ACCELERATES COMMERCIAL BUILD-UP IN THE U.S..IN 2019, ZEALAND EXPECTS REVENUE FROM EXISTING LICENSE AGREEMENTS.HOWEVER, SINCE SUCH REVENUE IS UNCERTAIN IN TERMS OF SIZE AND TIMING, ZEALAND DOES NOT GUIDE ON SUCH REVENUE..NET OPERATING EXPENSES IN 2019 ARE NOW EXPECTED TO BE WITHIN DKK 580-600 MILLION, CHANGED FROM PREVIOUS DKK 550-570 MILLION.CHANGE IN GUIDANCE IS MAINLY RELATED TO STRONG CLINICAL PROGRESS RESULTING IN ADDITIONAL SPEND ON ZP7570 AND DASIGLUCAGON CHI PROGRAMS, AND ACCELERATED BUILD-UP IN U.S. TO PREPARE FOR COMMERCIALIZATION OF GLEPAGLUTIDE AND DASIGLUCAGON.H1 REVENUE OF DKK 19.9 MILLION / USD 3.0 MILLION (DKK 24.9 MILLION / USD 3.9 MILLION IN FIRST SIX MONTHS OF 2018).H1 NET OPERATING RESULT OF DKK -272.1 MILLION / USD -41.5 MILLION (DKK -203.5 MILLION / USD -31.8 MILLION IN FIRST SIX MONTHS OF 2018).

Zealand Pharma Executive Vice President And CSO Andrew Parker To Step Down

July 29 (Reuters) - Zealand Pharma A/S <ZELA.CO>::REG-ZEALAND PHARMA ANNOUNCES CHANGE IN CORPORATE MANAGEMENT.ANDREW PARKER HAS ACCEPTED A TOP EXECUTIVE LEADERSHIP POSITION IN A NON-COMPETING BIOTECHNOLOGY COMPANY OUTSIDE DENMARK.HE WILL REMAIN IN HIS ROLE WITH ZEALAND PHARMA UNTIL AUGUST 31, 2019.PROCESS TO HIRE A NEW CHIEF SCIENTIFIC OFFICER IS WELL UNDERWAY.RIE SCHULTZ HANSEN, VICE PRESIDENT OF RESEARCH AT ZEALAND PHARMA, HAS BEEN APPOINTED AS INTERIM DEPARTMENT LEAD UNTIL NEW PERMANENT CSO IS IN PLACE.

Zealand Pharma Total Proceeds From Capital Increase Amount To DKK 9.0 Mln

June 14 (Reuters) - Zealand Pharma A/S <ZELA.CO>::REG-ZEALAND PHARMA INCREASES ITS SHARE CAPITAL AS A CONSEQUENCE OF EXERCISE OF EMPLOYEE WARRANTS.INCREASED ITS SHARE CAPITAL BY A NOMINAL AMOUNT OF DKK 89,315 DIVIDED INTO 89,315 NEW SHARES.EXERCISE PRICE WAS DKK 101.20 PER SHARE.TOTAL PROCEEDS TO ZEALAND FROM CAPITAL INCREASE AMOUNT TO DKK 9,038,678.00.

Beta Bionics And Zealand Pharma Announce Superior Glycemic Control In Phase 2 Trial Of iLet

June 6 (Reuters) - Zealand Pharma A/S <ZELA.CO>::REG-BETA BIONICS AND ZEALAND PHARMA ANNOUNCE SUPERIOR GLYCEMIC CONTROL IN PHASE 2 HOME-USE CLINICAL TRIAL TESTING THE ILET™ BIONIC PANCREAS USING DASIGLUCAGION.FIRST HOME-USE TRIAL OF ILET BIONIC PANCREAS SYSTEM USING PRE-FILLED CARTRIDGES OF DASIGLUCAGON COMPATIBLE WITH ILET HAS BEEN SUCCESSFULLY COMPLETED.ILET THERAPY WAS INITIALIZED WITH BODY WEIGHT ONLY, WITH NO DEVICE TRAINING PERIODS, AND WITH NO PHYSICIAN INTERVENTION TO OPTIMIZE THERAPY.PRELIMINARY STUDY RESULTS REVEAL SUPERIOR BLOOD GLUCOSE CONTROL DURING STUDY PERIOD THAT USED BIHORMONAL CONFIGURATION OF ILET WITH DASIGLUCAGON COMPARED TO PERIOD THAT USED INSULIN-ONLY CONFIGURATION.

Zealand Pharma Q1 Net Operating Loss Widens To DKK 135.8 Million

May 16 (Reuters) - Zealand Pharma A/S <ZELA.CO>::REG-ZEALAND PHARMA INITIATES SEVERAL PHASE 3 STUDIES AND GROWS CASH POSITION IN THE FIRST QUARTER OF 2019.IN 2019, EXPECTS REVENUE FROM NEW POTENTIAL PARTNERSHIP AGREEMENTS AND FROM MILESTONES FROM EXISTING LICENSE AGREEMENTS.NET OPERATING EXPENSES IN 2019 ARE EXPECTED TO BE WITHIN DKK 550-570 MILLION.Q1 NET OPERATING LOSS DKK 135.8 MILLION VERSUS LOSS DKK 88.5 MILLION YEAR AGO.Q1 REVENUE DKK 0.0 MILLION VERSUS DKK 9.7 MILLION YEAR AGO.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up